9 5 9 4 4
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.3 Breast Cancer (Dove Med Press)
- 3.4 Clin Epidemiol
- 2.5 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.5 Clin Interv Aging
- 4.7 Drug Des Dev Ther
- 2.7 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.5 Int J Women's Health
- 2.5 Neuropsych Dis Treat
- 2.7 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.3 Ther Clin Risk Manag
- 2.5 J Pain Res
- 2.8 Diabet Metab Synd Ob
- 2.8 Psychol Res Behav Ma
- 3.0 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.7 Risk Manag Healthc Policy
- 4.2 J Inflamm Res
- 2.1 Int J Gen Med
- 4.2 J Hepatocell Carcinoma
- 3.7 J Asthma Allergy
- 1.9 Clin Cosmet Investig Dermatol
- 2.7 J Multidiscip Healthc
已发表论文
染色体过客复合体蛋白特征模型可以用来预测非小细胞肺癌 (NSCLC) 较差的预后情况
Authors Xia R, Chen S, Chen Y, Zhang W, Zhu R, Deng A
Published Date April 2015 Volume 2015:8 Pages 721—726
DOI http://dx.doi.org/10.2147/OTT.S81328
Received 21 January 2015, Accepted 3 March 2015, Published 7 April 2015
Aim: The chromosomal passenger complex (CPC) acts as a key modulator for
mitosis and cell cytokinesis. High levels of CPC proteins are frequently
observed in multiple cancers and are correlated with more progressive malignant
behaviors. The aim of the study was to evaluate whether CPC components or their
combinations could be used to assess the clinical risk of patients with
non-small-cell lung cancer (NSCLC).
Methods: The expression levels of four CPC proteins – aurora B kinase (AURKB), borealin, inner centromere protein (INCENP), and survivin – were evaluated using immunohistochemistry in an independent cohort of NSCLC specimens. A molecular predictor model was developed based on the combination of the four CPC proteins.
Results: All the CPC components were overexpressed in NSCLC tumors compared with their paired adjacent normal lung tissues. Survivin overexpression was significantly correlated with late tumor stage (P =0.0166). High expressions of AURKB, INCENP, and survivin, but not borealin, were associated with shorter survival in patients with NSCLC. The constructed 4-CPC-gene model divided the cohort into two different subgroups with significantly different prognoses (hazard ratio, HR =2.8915 [95% confidence interval, CI: 1.5187–5.5052]; P =0.0013) and was retained as an independent prognostic factor in multivariate analysis (HR =2.4398 [95% CI: 1.2631–4.7127], P =0.0082). Moreover, the 4-CPC-gene model demonstrated a higher predictive ability for overall survival than each individual CPC biomarker.
Conclusion: Taken together, our study suggests that a molecular prognostic model based on simultaneous detection of CPC components could serve as a complement to current clinical risk stratification approaches for patients with NSCLC.
Keywords: non-small-cell lung cancer, chromosomal passenger complex, AURKB, survivin, borealin, INCENP
Methods: The expression levels of four CPC proteins – aurora B kinase (AURKB), borealin, inner centromere protein (INCENP), and survivin – were evaluated using immunohistochemistry in an independent cohort of NSCLC specimens. A molecular predictor model was developed based on the combination of the four CPC proteins.
Results: All the CPC components were overexpressed in NSCLC tumors compared with their paired adjacent normal lung tissues. Survivin overexpression was significantly correlated with late tumor stage (P =0.0166). High expressions of AURKB, INCENP, and survivin, but not borealin, were associated with shorter survival in patients with NSCLC. The constructed 4-CPC-gene model divided the cohort into two different subgroups with significantly different prognoses (hazard ratio, HR =2.8915 [95% confidence interval, CI: 1.5187–5.5052]; P =0.0013) and was retained as an independent prognostic factor in multivariate analysis (HR =2.4398 [95% CI: 1.2631–4.7127], P =0.0082). Moreover, the 4-CPC-gene model demonstrated a higher predictive ability for overall survival than each individual CPC biomarker.
Conclusion: Taken together, our study suggests that a molecular prognostic model based on simultaneous detection of CPC components could serve as a complement to current clinical risk stratification approaches for patients with NSCLC.
Keywords: non-small-cell lung cancer, chromosomal passenger complex, AURKB, survivin, borealin, INCENP
